We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Walks Away From Rituxan Biosimilar in the U.S.
Sandoz Walks Away From Rituxan Biosimilar in the U.S.
Novartis subsidiary Sandoz abandoned its pursuit of U.S. approval for its biosimilar of Roche’s blockbuster cancer drug Rituxan (rituximab) and said it plans to focus on other products in the biosimilar pipeline.